The sensitivity of acute myeloid leukemia to CDK8/19 inhibitors is determined by their metabolic profile
Ekaterina A. Varlamova, Daria V. Andreeva, Alexandra A. Dalina, Alexander V. Ivanov, Artemy P. Fedulov, Elena V Misnik, Natalia Pavlenko, Alexandra V. Bruter, Victor Vyacheslavovich Tatarskiy
This study identifies that acute myeloid leukemia (AML) sensitivity to CDK8/19 inhibitors is linked to their metabolic profile, specifically glycolytic activity and TCA disruption.
Biology Direct · Sep 14, 2026Peer-reviewedCell Biology